ArticleEndocrinology, diabetes & metabolism case reports2025
Diffuse thyroid enlargement and its regression in methotrexate-associated lymphoproliferative disorder: an ultrasonographic observation.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: A 70-year-old woman with Hashimoto thyroiditis, treated with levothyroxine, was diagnosed with rheumatoid arthritis 1 year prior and subsequently began methotrexate (MTX) therapy. She presented with a 2-week history of progressive, painless anterior neck swelling. Ultrasonography (US) revealed diffuse thyroid enlargement with heterogeneously decreased echogenicity, and laboratory tests showed an elevated thyroid stimulating hormone (TSH) level of 63.6 mIU/L. A core needle biopsy confirmed the presence of mucosa-associated lymphoid tissue (MALT) lymphoma. Given her MTX therapy, MTX-associated lymphoproliferative disorder (MTX-LPD) was strongly suspected. Accordingly, MTX was discontinued, and her levothyroxine dosage was increased. Serial US examinations subsequently demonstrated a gradual reduction in thyroid size, and this progressive regression ultimately confirmed the diagnosis of MTX-LPD. Although MTX-LPD is a recognized complication of MTX therapy in rheumatoid arthritis, its primary occurrence in the thyroid is rare. In previous reports, primary thyroid lymphoma was either diagnosed in patients with a preexisting diagnosis of Hashimoto thyroiditis or concurrently with it. However, in our case, she already had Hashimoto thyroiditis, and the onset of MTX-LPD was accompanied by a worsening of hypothyroidism. Most patients with MTX-LPD achieve remission following MTX withdrawal. This rare case documents the natural improvement of diffuse ultrasonographic findings in thyroid MTX-LPD, highlighting the usefulness of serial ultrasonographic monitoring in patient follow-up. Learning points: Patients receiving MTX therapy may develop MTX-LPD involving the thyroid gland. Thyroid MTX-LPD may present with concomitant worsening of hypothyroidism. Ultrasonographic findings in thyroid MTX-LPD can occasionally include diffuse thyroid enlargement. MALT lymphoma may occur as the histological subtype in primary thyroid MTX-LPD. MTX-LPD is expected to regress following discontinuation of MTX. Serial ultrasonographic monitoring of thyroid size can serve as an effective guide for assessing MTX-LPD regression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.